Literature DB >> 10919672

Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest.

M Srethapakdi1, F Liu, R Tavorath, N Rosen.   

Abstract

The ansamycin antibiotics, herbimycin A (HA) and geldanamycin (GM), bind to a conserved pocket in heat shock protein 90 (Hsp90) and alter the function of this chaperone protein. Occupancy of this pocket results in the degradation of a subset of signaling molecules. These include proteins known to associate with Hsp90, e.g., the steroid receptors and Raf, as well as certain transmembrane tyrosine kinases, such as the ErbB receptor family. In a variety of tumor cell lines, treatment with HA potently inhibited cellular proliferation by inducing G1 arrest. This arrest was accompanied by hypophosphorylation of the retinoblastoma gene product (RB) and rapid down-regulation of cyclin D- and E-associated kinase activities. Inhibition of kinase activity was found to result from loss in expression of cyclins D1, D3, and E, as well as the associated cyclin-dependent kinases, cyclin-dependent kinase 4 and cyclin-dependent kinase 6. In addition, HA treatment also caused a late induction of p27(Kip1) protein. The loss of cyclin D preceded the other effects of HA, suggesting that it might be the primary cause of G1 arrest. To determine whether the effects of HA are mediated by selective inhibition of the cyclin D-RB pathway, HA was added to tumor cell lines lacking functional RB. HA treatment of Rb-negative tumor cell lines failed to elicit a G1 arrest. In addition, after release from synchronization with nocodazole, Rb-negative but not Rb-positive cell lines were able to progress through G1 into S phase in the presence of HA. Together, these findings suggest that induction of G1 arrest by HA results from down-regulation of cyclin D expression and its associated kinase activity. Furthermore, these findings imply that Hsp90 selectively regulates signaling pathways upstream of RB.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10919672

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

Review 1.  Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.

Authors:  Xiangyi Lu; Li Xiao; Luan Wang; Douglas M Ruden
Journal:  Biochem Pharmacol       Date:  2011-11-22       Impact factor: 5.858

2.  Development of quantitative and high-throughput assays of polyomavirus and papillomavirus DNA replication.

Authors:  Amélie Fradet-Turcotte; Geneviève Morin; Michaël Lehoux; Peter A Bullock; Jacques Archambault
Journal:  Virology       Date:  2010-01-15       Impact factor: 3.616

3.  Inhibition of HSP90 in Trypanosoma cruzi induces a stress response but no stage differentiation.

Authors:  Sebastian E B Graefe; Martina Wiesgigl; Iris Gaworski; Andrea Macdonald; Joachim Clos
Journal:  Eukaryot Cell       Date:  2002-12

4.  Heat shock protein 90 inhibition depletes LATS1 and LATS2, two regulators of the mammalian hippo tumor suppressor pathway.

Authors:  Catherine J Huntoon; Monica D Nye; Liyi Geng; Kevin L Peterson; Karen S Flatten; Paul Haluska; Scott H Kaufmann; Larry M Karnitz
Journal:  Cancer Res       Date:  2010-09-14       Impact factor: 12.701

5.  Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis.

Authors:  Bumsup Kwon; Pravir Kumar; Han-Kyu Lee; Ling Zeng; Kenneth Walsh; Qinghao Fu; Amey Barakat; Henry W Querfurth
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

6.  90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.

Authors:  Archie N Tse; Tahir N Sheikh; Ho Alan; Ting-Chao Chou; Gary K Schwartz
Journal:  Mol Pharmacol       Date:  2008-09-26       Impact factor: 4.436

7.  HSP90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way.

Authors:  Bin Peng; Limin Xu; Fanfan Cao; Tingxuan Wei; Chunxin Yang; Georges Uzan; Denghai Zhang
Journal:  Mol Cancer       Date:  2010-04-16       Impact factor: 27.401

8.  Induction of premature senescence by hsp90 inhibition in small cell lung cancer.

Authors:  Ian J Restall; Ian A J Lorimer
Journal:  PLoS One       Date:  2010-06-11       Impact factor: 3.240

9.  SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers.

Authors:  Sarat Chandarlapaty; Ayana Sawai; Qing Ye; Anisa Scott; Melanie Silinski; Ken Huang; Pat Fadden; Jeff Partdrige; Steven Hall; Paul Steed; Larry Norton; Neal Rosen; David B Solit
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

10.  The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors.

Authors:  Sudhakar Voruganti; Jeff C Lacroix; Chelsea N Rogers; Janet Rogers; Robert L Matts; Steven D Hartson
Journal:  J Proteome Res       Date:  2013-06-27       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.